Status:

UNKNOWN

China Intensive Lipid Lowering With Statins in Acute Coronary Syndrome

Lead Sponsor:

Ministry of Science and Technology of the People´s Republic of China

Conditions:

Acute Coronary Syndrome

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

In summary, the CHILLAS study will be the first multicenter study performed in a Chinese population using a patient-level analysis to compare the effects and safety of intensive statin therapy with th...

Detailed Description

The CHILLAS study is planned to evaluate whether intensive treatment with statins for 2 years results in a reduction of cardiovascular events in patients with ACS. A total of 1,600 patients will be ra...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of acute coronary syndrome
  • Clinically stable for 24 hours

Exclusion

  • Hypersensitive to statins
  • Receiving therapy with atorvastatin at a dose greater than 20 mg per day before enrollment or lipid-lowering therapy with fibric acid derivatives or niacin that can not be discontinued
  • Having a coexisting condition that shortened expected survival to less than two years
  • Having obstructive hepatobiliary disease or other serious hepatic or kidney disease
  • Having an unexplained elevation in the creatine kinase level that was more than three times the upper limit of normal and that was not related to myocardial infarction
  • Having undergone surgery or serious trauma within the preceding two months
  • Having been in the final stage of chronic congestive heart failure
  • Having a baseline level of LDL cholesterol less than 50mg/dl

Key Trial Info

Start Date :

December 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2010

Estimated Enrollment :

1600 Patients enrolled

Trial Details

Trial ID

NCT00728013

Start Date

December 1 2006

End Date

December 1 2010

Last Update

August 25 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Second Xiangya Hospital of Central South University

Changsha, Hunan, China, 410011